Axogen (AXGN) Q2 2026: Revenue Jumps 23% on Breast Segment Surge
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Axogen topped both earnings and revenue expectations while lifting full-year guidance on the back of explosive 50%+ growth in its Breast segment, a shift that's now reshaping the company's revenue mix and fueling a 23% year-over-year sales jump.
Continue ReadingShow less
Axogen reported Q2 2026 revenue of $69.7 million, beating the consensus estimate of roughly $67.1 million by about 4% and marking a 23% jump from the $47.9 million the company posted in Q2 2024. Earnings per share came in at $0.12, just ahead of the $0.1186 estimate. The results capped a steady climb in quarterly revenue that has accelerated sharply since mid-2025.
The standout driver was the Breast segment, which delivered growth exceeding 50% and is now meaningfully reshaping Axogen's overall revenue mix. That shift is significant because Axogen built its reputation in peripheral nerve repair, so the Breast segment's rapid expansion signals the company is successfully diversifying its commercial footprint into reconstructive surgery alongside its core business.
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Management responded to the momentum by raising full-year guidance, a sign of confidence that the Breast segment's growth is not a one-quarter anomaly. With quarterly revenue now at $69.7 million compared to $61.5 million just one quarter prior, investors will be watching whether that trajectory holds through the back half of the fiscal year.
Mentioned: AXGN